GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Guizhou Bailing Group Pharmaceutical Co Ltd (SZSE:002424) » Definitions » Change In Receivables

Guizhou Bailing Group Pharmaceutical Co (SZSE:002424) Change In Receivables : ¥0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Guizhou Bailing Group Pharmaceutical Co Change In Receivables?

Guizhou Bailing Group Pharmaceutical Co's change in receivables for the quarter that ended in Mar. 2024 was ¥0 Mil. It means Guizhou Bailing Group Pharmaceutical Co's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Guizhou Bailing Group Pharmaceutical Co's change in receivables for the fiscal year that ended in Dec. 2023 was ¥-35 Mil. It means Guizhou Bailing Group Pharmaceutical Co's Accounts Receivable increased by ¥35 Mil from Dec. 2022 to Dec. 2023 .

Guizhou Bailing Group Pharmaceutical Co's Accounts Receivable for the quarter that ended in Mar. 2024 was ¥2,389 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Guizhou Bailing Group Pharmaceutical Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 163.59.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Guizhou Bailing Group Pharmaceutical Co's liquidation value for the three months ended in Mar. 2024 was ¥-1,600 Mil.


Guizhou Bailing Group Pharmaceutical Co Change In Receivables Historical Data

The historical data trend for Guizhou Bailing Group Pharmaceutical Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guizhou Bailing Group Pharmaceutical Co Change In Receivables Chart

Guizhou Bailing Group Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 145.33 -163.74 193.73 -182.70 -34.97

Guizhou Bailing Group Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Guizhou Bailing Group Pharmaceutical Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guizhou Bailing Group Pharmaceutical Co  (SZSE:002424) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Guizhou Bailing Group Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=2389.302/1332.744*91
=163.59

2. In Ben Graham's calculation of liquidation value, Guizhou Bailing Group Pharmaceutical Co's accounts receivable are only considered to be worth 75% of book value:

Guizhou Bailing Group Pharmaceutical Co's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=298.905-4300.274+0.75 * 2389.302+0.5 * 1218.788
=-1,600

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guizhou Bailing Group Pharmaceutical Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Guizhou Bailing Group Pharmaceutical Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Guizhou Bailing Group Pharmaceutical Co (SZSE:002424) Business Description

Traded in Other Exchanges
N/A
Address
Economic and Technological Development Zone, Air Boulevard West, Anshun City, CHN, 561000
Guizhou Bailing Group Pharmaceutical Co Ltd is a China-based company. It is engaged in the production and sale of medicinal tablets, capsules, and syrups.
Executives
Jiang Wei Director
Jiang Yong Directors, executives
Chen Pei Directors, executives
Kuang Xun Hua Director
Niu Min Directors, Directors, and Executives
Chen Zhi Securities Affairs Representative
Zheng Rong Executives
Li Qiang Supervisors
Xia Wen Supervisors
Wang Xiao Dong Supervisors
Teng Chun Jie Supervisors
Li Hui Fang Supervisors
Zhang Jin Fen Director
Cai Shou Xian Executives

Guizhou Bailing Group Pharmaceutical Co (SZSE:002424) Headlines

No Headlines